2018
Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis
Aaen G, Waltz M, Vargas W, Makhani N, Ness J, Harris Y, Casper TC, Benson L, Candee M, Chitnis T, Gorman M, Graves J, Greenberg B, Lotze T, Mar S, Tillema JM, Rensel M, Rodriguez M, Rose J, Rubin J, Schreiner T, Waldman A, Weinstock-Guttman B, Belman A, Waubant E, Krupp L. Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis. Journal Of Child Neurology 2018, 34: 148-152. PMID: 30556452, PMCID: PMC6579723, DOI: 10.1177/0883073818815041.Peer-Reviewed Original ResearchConceptsPediatric multiple sclerosisMultiple sclerosisEarly developmental milestonesPediatric Multiple Sclerosis CentersPediatric-onset multiple sclerosisMultiple sclerosis onsetMultiple Sclerosis CenterDevelopmental milestonesPediatric controlsDisease onsetHealthy controlsSclerosisAge 18Age 11ChildrenOnsetIndividualized education planFurther researchControl
2017
Genetic and Environmental Risk Factors for Pediatric Multiple Sclerosis
Makhani N, George I. Genetic and Environmental Risk Factors for Pediatric Multiple Sclerosis. Journal Of Pediatric Neurology 2017, 16: 141-147. DOI: 10.1055/s-0037-1604339.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsEnvironmental risk factorsMultiple sclerosisRisk factorsLow serum vitamin D levelsSerum vitamin D levelsNon-HLA single nucleotide polymorphismsVitamin D levelsPediatric multiple sclerosisEpstein-Barr virusHuman leukocyte antigenDifferent risk factorsGenetic risk factorsD levelsLeukocyte antigenParental smokingPrior exposureSingle nucleotide polymorphismsSclerosisCurrent literatureNucleotide polymorphismsChildrenFactorsSmokingAntigenDisease
2016
Pediatric multiple sclerosis
Ghezzi A, Amato MP, Makhani N, Shreiner T, Gärtner J, Tenembaum S. Pediatric multiple sclerosis. Neurology 2016, 87: s97-s102. PMID: 27572869, DOI: 10.1212/wnl.0000000000002823.Peer-Reviewed Original ResearchConceptsFirst-line treatmentPediatric multiple sclerosisMultiple sclerosisObservational studyRandomized placebo-controlled trialStandard first-line treatmentFirst-line treatment optionRelapsing-remitting multiple sclerosisPlacebo-controlled trialAcceptable safety profilePediatric age groupDisease-modifying therapiesPediatric MSGlatiramer acetateRelapse rateUnblinded trialSafety profileTreatment optionsDisease progressionExpert guidelinesAge groupsSclerosisTrialsCurrent knowledgeTreatmentInternational Pediatric MS Study Group Global Members Symposium report
Wassmer E, Chitnis T, Pohl D, Amato MP, Banwell B, Ghezzi A, Hintzen RQ, Krupp LB, Makhani N, Rostásy K, Tardieu M, Tenembaum S, Waldman A, Waubant E, Kornberg AJ. International Pediatric MS Study Group Global Members Symposium report. Neurology 2016, 87: s110-s116. PMID: 27572855, PMCID: PMC10688073, DOI: 10.1212/wnl.0000000000002880.Peer-Reviewed Original ResearchConceptsPediatric multiple sclerosisMultiple sclerosisInternational Pediatric Multiple Sclerosis Study GroupMultiple Sclerosis Study GroupOptimal vitamin D intakeEarly-onset multiple sclerosisNewer MS agentsAcute disseminated encephalomyelitisVitamin D intakeVitamin D deficiencyChildhood multiple sclerosisLong-term outcomesDrug treatment optionsDiverse patient samplesDifferentiation of MSEffective cognitive rehabilitationD intakeDisseminated encephalomyelitisD deficiencyNeuroinflammatory disordersNeuromyelitis opticaMS riskTreatment optionsMS outcomesClinical trialsOral Dimethyl Fumarate in Children With Multiple Sclerosis: A Dual-Center Study
Makhani N, Schreiner T. Oral Dimethyl Fumarate in Children With Multiple Sclerosis: A Dual-Center Study. Pediatric Neurology 2016, 57: 101-104. PMID: 26996405, DOI: 10.1016/j.pediatrneurol.2016.01.010.Peer-Reviewed Original ResearchConceptsOral dimethyl fumarateMultiple sclerosisDimethyl fumarateSide effectsFirst-line injectable therapiesBrain magnetic resonance imagingAbnormal liver transaminasesDual-Center ExperienceUsual adult doseMonths of therapyNew T2 lesionsFirst-line therapyCommon side effectsMagnetic resonance imaging (MRI) parametersPediatric multiple sclerosisDual-center studyChildren 18 yearsFormal clinical trialsMagnetic resonance imagingLiver transaminasesDisability scoresLaboratory abnormalitiesOral medicationsRelapse rateRetrospective review
2011
Environmental Risk Factors for Paediatric Multiple Sclerosis
Makhani N, Banwell B. Environmental Risk Factors for Paediatric Multiple Sclerosis. European Neurological Review 2011, 6: 175. DOI: 10.17925/enr.2011.06.03.175.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMultiple sclerosisEnvironmental risk factorsRisk factorsAberrant immune responsePediatric multiple sclerosisCommon neurological disorderChildhood environmental exposuresDisease prevention strategiesImmune responseStudy of childrenPrevention strategiesNeurological disordersPediatric researchEnvironmental exposuresSclerosisCurrent understanding
2010
Environmental Risk Factors for Pediatric Multiple Sclerosis
Makhani N, Banwell B. Environmental Risk Factors for Pediatric Multiple Sclerosis. TouchREVIEWS In Neurology 2010, 06: 96. DOI: 10.17925/usn.2010.06.02.96.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMultiple sclerosisEnvironmental risk factorsRisk factorsAberrant immune responsePediatric multiple sclerosisCommon neurologic disorderChildhood environmental exposuresDisease prevention strategiesNeurologic disordersImmune responseStudy of childrenPrevention strategiesPediatric researchEnvironmental exposuresSclerosisCurrent understanding